MedTrace Logo

The BARCODE 1 Pilot Study

NCT03158922 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 329

Last updated 2025-09-26

No results posted yet for this study

Summary

BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. This study forms a pilot of 300 men, with the view to continue to a future study of 5000 men.

Conditions

Interventions

GENETIC

Genetic SNP profiling

Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.

OTHER

Prostate cancer screening

Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.

PROCEDURE

Prostate biopsy

Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.

Sponsors & Collaborators

  • Institute of Cancer Research, United Kingdom

    lead OTHER

Principal Investigators

  • Rosalind A Eeles, FRCP, FRFR · Institute of Cancer Research and Royal Marsden Hospital

Eligibility

Min Age
55 Years
Max Age
69 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-04-29
Primary Completion
2018-04-14
Completion
2028-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03158922 on ClinicalTrials.gov